Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1403-1410

  Urtreger, Alejandro J ^a   Werbajh, Santiago E ^a   Verrecchia, Frank ^b   Mauviel, Alain ^b   Puricelli, Lydia I ^a   Kornblihtt, Alberto R ^a   Bal De Kier Joffé, Elisa D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

cDNA arrays; Fibronectin; Metastasizing ability; Murine mammary adenocarcinoma

Indexed keywords

FIBRONECTIN;

ADENOCARCINOMA; ANIMAL; ARTICLE; COMPARATIVE STUDY; DNA MICROARRAY; DOWN REGULATION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; DOWN-REGULATION; FEMALE; FIBRONECTINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 34547700279     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1403     Document Type: Article

References (43)

1. Condeelis J, Singer RH and Segall JE: The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 21: 695-718, 2005. (Pubitemid 41740651)
2. Wittekind C and Neid M: Cancer invasion and metastasis. Oncology 69 (Suppl 1): 14-16, 2005. (Pubitemid 41433536)
3. Ludwig T: Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 27: 1181-1191, 2005.
4. Minn AJ, Kang Y, Serganova I, et al: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44-55, 2005. (Pubitemid 40385504)
5. Puricelli L, Gomez DE, Vidal MC, et al: Effect of host-organ environment on the in vivo and in vitro behavior of a murine mammary adenocarcinoma. Tumour Biol 15: 284-293, 1994. (Pubitemid 24360698)
6. Ladeda V, Adam AP, Puricelli L and Bal de Kier JE: Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis. Breast Cancer Res Treat 69: 39-51, 2001. (Pubitemid 33079028)
7. Henrique R, Jeronimo C, Teixeira MR, et al: Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4: 1-8, 2006. (Pubitemid 43259884)
8. Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38: 2651-2660, 1978.
9. Bal de Kier Joffe E, Puricelli L, Vidal MC and De Lustig ES: Characterization of two murine mammary tumors with different metastatic ability. J Exp Clin Cancer Res 2: 151-160, 1983. (Pubitemid 13078358)
10. Urtreger AJ, Ladeda VE, Puricelli LI, et al: Modulation of fibronectin expression and proteolytic activity associated to the invasive and metastatic phenotype in two new murine mammary tumor cell lines. Int J Oncol 11: 489-496, 1997. (Pubitemid 27364280)
11. Werbajh SE, Urtreger AJ, Puricelli LI, De Lustig ES, Bal de Kier Joffe E and Kornblihtt AR: Downregulation of fibronectin transcription in highly metastatic adenocarcinoma cells. FEBS Lett 440: 277-281, 1998. (Pubitemid 29052298)
12. Muro A, Puricelli L, Kornblihtt AR and Bal de Kier Joffe E: Inverse correlation between fibronectin mRNA levels and the metastatic potential of two murine mammary adenocarcinomas. Invasion Metastasis 11: 281-287, 1991.
13. Bal de Kier Joffe E, Puricelli L and De Lustig ES: Modified adhesion behavior after in vitro passage of two related murine mammary adenocarcinomas with different metastasizing ability. Invasion Metastasis 6: 302-312, 1986.
14. Pereyra-Alfonso S, Haedo A and Bal de Kier JE: Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. Int J Cancer 42: 59-63, 1988.
15. Daroqui MC, Puricelli LI, Urtreger AJ, Elizalde PV, Lanuza GM and Bal de Kier Joffe E: Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas. Breast Cancer Res Treat 80: 287-301, 2003. (Pubitemid 37046753)
16. Kaspar M, Zardi L and Neri D: Fibronectin as target for tumor therapy. Int J Cancer 118: 1331-1339, 2006.
17. Urtreger A, Porro F, Puricelli L, et al: Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int J Cancer 78: 233-241, 1998. (Pubitemid 28443182)
18. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470, 2003. (Pubitemid 36432420)
19. Yu J, Moon A and Kim HR: Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 282: 697-700, 2001. (Pubitemid 32924612)
20. Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998. (Pubitemid 28411130)
21. Huang S, Bucana CD, van Arsdall M and Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21: 2504-2512, 2002. (Pubitemid 34438103)
22. Pansky A, Hildebrand P, Fasler-Kan E, et al: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85: 720-725, 2000. (Pubitemid 30080488)
23. Wu F, Li JQ, Miki H, et al: p107 expression in colorectal tumours rises during carcinogenesis and falls during invasion. Eur J Cancer 38: 1838-1848, 2002. (Pubitemid 35247469)
24. Botos J, Barhoumi R, Burghardt R and Kochevar DT: Rb localization and phosphorylation kinetics correlate with the cellular phenotype of cultured breast adenocarcinoma cells. In Vitro Cell Dev Biol Anim 38: 235-241, 2002. (Pubitemid 34975848)
25. Berx G and van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293, 2001. (Pubitemid 32851157)
26. Lim SC and Lee MS: Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9: 915-928, 2002.
27. Cavallaro U and Christofori G: Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 1552: 39-45, 2001. (Pubitemid 34066627)
28. Indinnimeo M, Cicchini C, Stazi A, et al: Prognostic impact of CD31 antigen expression in anal canal carcinoma. Hepatogastroenterology 48: 1355-1358, 2001. (Pubitemid 33010424)
29. Tang DG, Chen YQ, Newman PJ, et al: Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 268: 22883-22894, 1993. (Pubitemid 23318353)
30. Righi L, Deaglio S, Pecchioni C, et al: Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol 162: 1163-1174, 2003. (Pubitemid 36355924)
31. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L and Bal de Kier JE: Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40: 209-223, 1996. (Pubitemid 26336116)
32. Monitto CL, Berkowitz D, Lee KM, et al: Differential gene expression in a murine model of cancer cachexia. Am J Physiol Endocrinol Metab 281: E289-E297, 2001.
33. Akiyama SK, Olden K and Yamada KM: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14: 173-189, 1995.
34. Christensen L: The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS 26 (Suppl): 1-39, 1992.
35. Wierzbicka-Patynowski I and Schwarzbauer JE: The ins and outs of fibronectin matrix assembly. J Cell Sci 116: 3269-3276, 2003. (Pubitemid 37038975)
36. Akamatsu H, Ichihara-Tanaka K, Ozono K, Kamiike W, Matsuda H and Sekiguchi K: Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. Cancer Res 56: 4541-4546, 1996. (Pubitemid 26330468)
37. Zhao H, Jhanwar-Uniyal M, Datta PK, et al: Expression profile of genes associated with antimetastatic gene: nm23-mediated metastasis inhibition in breast carcinoma cells. Int J Cancer 109: 65-70, 2004. (Pubitemid 38160663)
38. Schalken JA, Ebeling SB, Isaacs JT, et al: Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Res 48: 2042-2046, 1988.
39. Urtreger AJ, Aguirre Ghiso JA, Werbajh SE, Puricelli LI, Muro AF and Bal de Kier Joffe E: Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. Int J Cancer 82: 748-753, 1999. (Pubitemid 29356976)
40. Muro AF, Bernath VA and Kornblihtt AR: Interaction of the -170 cyclic AMP response element with the adjacent CCAAT box in the human fibronectin gene promoter. J Biol Chem 267: 12767-12774, 1992.
41. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K and Joensuu H: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9: 68-75, 2003. (Pubitemid 36109717)
42. Mackay A, Jones C, Dexter T, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003. (Pubitemid 36605615)
43. Hao X, Sun B, Hu L, et al: Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100: 1110-1122, 2004. (Pubitemid 38325937)